Home
Portfolio
Strategy
Team
News
Contact
Investor Login
Home
Portfolio
Strategy
Team
News
Contact
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
Read Article
News
2021
2020
Archive
March 2, 2021
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
March 2, 2021
Impel Neuropharma Announces Key Management Team Appointments as Company Advances Toward Commercialization in 2021
March 1, 2021
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
March 1, 2021
Pear Therapeutics Announces Second Closing of Series D Financing
February 26, 2021
Artiva Raises $120M in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
February 24, 2021
Pear Therapeutics Announces Publication of Economic Analysis Showing Cost-Effectiveness of reSET-O in Treating Opioid Use Disorder
February 24, 2021
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA
February 22, 2021
IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day
February 17, 2021
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors
February 17, 2021
Pear Announces Indiana Family and Social Services Administration Division of Mental Health and Addiction Will Provide Access to Prescription Digital Therapeutics for Substance Use and Opioid Use Disorders
1
2
3
…
76
Next Page »
